Selected transactions
To reflect healthcare trailblazers, we are shifting our focus to an integrative healthcare approach from therapeutics to personalized and preventive medicine, anti- and better-aging, healthy well-being and lifestyle.
Please find below selected transactions completed by WINDOME BANKING PARTNERS’ employees while at other Firms, except for the Suisselle-Sihuan Pharma Deal (June 2023).
Exclusive Financial Advisor in the acquisition of Marinomed GmbH, a Biotechnology company developping anti-viral and immunological treatments, including Carragelose® anti-viral eye drop program.
Exclusive Financial Advisor to Alternext listed Novacyt SA on a merger with Lab21 Ltd.
Exclusive Financial Advisor to NicOx SA on the acquisition of Eupharmed S.r.l for an upfront consideration combined with a performance earn-out.
Exclusive Financial Advisor to Ekomir’s shareholders on the sale of the company to Valeant Pharmaceuticals.
Financial Advisor to Vemedia’s shareholders on the sale of a 78% stake to IK Investment Partners and a minority MBO to CEO.
Exclusive Financial Advisor to Italian healthcare company Scharper SpA on the sale of a majority stake to Italy-based group IdB Holding SpA.
Exclusive advisor to Vaxon Biotech on a global collaboration partnership, including a call option arrangement an upfront and several clinical performance milestones with a major US oncology player.
Exclusive advisor to Biomérieux in the acquisition of AES Laboratoire, a leading French In-Vitro Diagnostics Group, specialized in industrial microbiological control.
Exclusive advisor, listing Sponsor and Sole Bookrunner for Novagali’s Initial Public Offering.
Exclusive Financial Advisor in the third-tranche of follow-on offerings corresponding to a capital increase with subscription rights for Transgene.
GSK Part of the Business Development Team which worked on the acquisition of dermatology specialty Pharma Stiefel.
Exclusive Financial Advisor to Institut Mérieux’s in the divestiture of a 78% majority stake in the Indian Prophylactic vaccine company Shantha Biotechnics to Sanofi-Aventis.